Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.

Biotech Giants' SG&A Expenses: A Decade of Growth

__timestampACADIA Pharmaceuticals Inc.Blueprint Medicines Corporation
Wednesday, January 1, 2014327480007890000
Thursday, January 1, 20159080400014456000
Friday, January 1, 201618645600019218000
Sunday, January 1, 201725506200027986000
Monday, January 1, 201826575800047928000
Tuesday, January 1, 201932563800096388000
Wednesday, January 1, 2020388661000157743000
Friday, January 1, 2021396028000195293000
Saturday, January 1, 2022369090000237374000
Sunday, January 1, 2023402466000295141000
Monday, January 1, 2024359272000
Loading chart...

Infusing magic into the data realm

SG&A Expenses: A Tale of Two Biotech Innovators

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Over the past decade, ACADIA Pharmaceuticals Inc. and Blueprint Medicines Corporation have demonstrated contrasting trajectories in their SG&A expenditures.

ACADIA Pharmaceuticals Inc.

From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, reflecting its aggressive expansion and marketing strategies. By 2023, their expenses reached approximately $402 million, highlighting a consistent upward trend.

Blueprint Medicines Corporation

In contrast, Blueprint Medicines saw a staggering increase of nearly 3,600% in the same period, with expenses peaking at around $295 million in 2023. This rapid growth underscores their strategic investments in administrative capabilities to support their innovative pipeline.

These trends reveal the dynamic nature of financial management in the biotech sector, where strategic spending can drive both growth and innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025